Here, a novel candidate EGFR-TKI, cAMP-H3BO3 complex, is investigated for its ability to reversibly bind to the EGFR ATP-binding site to prevent EGFR signal transduction and subsequently inhibit cancer cell growth. Here, EGFR is linked to cancer.